Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations

1 month ago

Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need…

HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing

1 month ago

NAPLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB:HLYK), a patient-centric healthcare technology company, announced today…

Daré Bioscience Receives $3.6 Million in Additional Grant Funding

1 month ago

Grant funding will support continued progress on a preclinical research program to identify and develop a non-hormonal intravaginal contraceptive innovation…

Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million

1 month ago

CHARLOTTE, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company…

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

1 month ago

Record-setting presence at ASH reflects widespread recognition of clonoSEQ as a standard-of-care tool for personalizing patient care and accelerating drug…

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

1 month ago

Oral macrocyclic peptides have the potential to offer biologic-like efficacy and safety in a convenient oral formatCollaboration further advances Biogen’s…

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

1 month ago

Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in…

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

1 month ago

HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision…

Functional Brands Issues Letter to Shareholders

1 month ago

Making Everyone Healthy Again: A Milestone Moment and Strategic Vision for GrowthLake Oswego, Oregon--(Newsfile Corp. - November 24, 2025) -…